Results 181 to 190 of about 3,328,836 (298)

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink. [PDF]

open access: yesVaccine
Yih WK   +14 more
europepmc   +1 more source

Analysis of regulatory review models and approval timelines across selected African medicines regulatory authorities using the OpERA framework (2020–2024)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background The World Health Organization (WHO) developed the Global Benchmarking Tool (GBT) to assess national regulatory systems and support regulatory‐system strengthening across regulatory functions. Several African National Medicines Regulatory Authorities (NMRAs) have achieved Maturity Level 3 (ML3).
Constance Sakala Chisha   +10 more
wiley   +1 more source

Rocavorexant, a novel, selective orexin‐1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Rocavorexant (INDV‐2000), a selective orexin‐1 receptor antagonist, reduces drug self‐administration and anxiety in nonclinical studies. This Phase 1 programme evaluated the safety, pharmacokinetics and pharmacodynamics of rocavorexant in healthy volunteers and treatment‐seeking individuals with opioid use disorder (OUD).
Martin Kankam   +5 more
wiley   +1 more source

Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network. [PDF]

open access: yesHum Vaccin Immunother
Viñeta Paramo M   +11 more
europepmc   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa   +14 more
wiley   +1 more source

The global extent of polypharmacy in neonatal intensive care: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Pharmaceutical treatment in the neonatal intensive care unit (NICU) is challenging, with neonates often receiving multiple drugs during hospitalization. Given their physiological immaturity, polypharmacy raises concerns about potential adverse effects, drug–drug interactions and the risk of supratherapeutic or subtherapeutic treatment.
Mia Finserås Bretun   +6 more
wiley   +1 more source

Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021-23. [PDF]

open access: yesHum Vaccin Immunother
Belongia EA   +12 more
europepmc   +1 more source

Adapting the WHO Global Competency Framework for Regulators of Medicines: Implementation lessons from the South African Health Products Regulatory Authority

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Medicines regulatory authorities require skilled staff to ensure timely, consistent and high‐quality regulatory decision making. The World Health Organization Global Competency Framework (WHO‐GCF) for Regulators of Medicines provides a common reference for defining regulatory workforce competencies while allowing adaptation to local needs.
Goonaseelan Pillai   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy